Cabozantinib not checked
Exelixis · XL184 · XL-184
FollowEvery change as it happens, and a Monday email
Trials
26 active
37 in total · 31 in the EU
Targets
—
None known yet
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “Tablets containing 60-mg or 20-mg cabozantinib once daily orally.”In the company’s words, NCT03690388 on ClinicalTrials.gov
- Tested for
- Differentiated Thyroid Cancer (2 trials), Hepatocellular Carcinoma (2 trials), Renal Cell Carcinoma (2 trials), Colorectal Cancer (2 trials), Medullary Thyroid Cancer, Metastatic Prostate Cancer, Prostate Adenocarcinoma, Cancer and 17 more
- Main trialPhase 4
- “The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.”In the company’s words, NCT01896479 on ClinicalTrials.gov
- Other names
- XL184 · Cabometyx · XL-184
Other drugs for Differentiated Thyroid Cancer
- EntrectinibRoche · Phase 1/2
- SelpercatinibEli Lilly · Phase 1/2
Coming up1
- 31 May 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials37
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 15 Jul 2020 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer | |
| Phase 3Active, not recruiting | 19 Aug 2020 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy | |
| Phase 3Active, not recruiting | 30 Nov 2021 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy | |
| Phase 3Active, not recruiting | 31 Jan 2022 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | |
| Phase 3Active, not recruiting | 19 Apr 2024 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | |
| Phase 3Enrolling by invitation | 31 May 2030 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | |
| Phase 1Active, not recruiting | 21 Feb 2023 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | |
| Phase 3Completed | 22 May 2015 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | |
| Phase 3Completed | 16 Oct 2017 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | |
| Phase 2Terminated | May 2011 | Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse | |
| Phase 2Completed | May 2013 | Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | |
| Phase 2Terminated | Nov 2014 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC | |
| Phase 3Authorised | not given | CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA | |
| Phase 2Authorised | not given | Immunological variables associated to ICI toxicity in cancer patients | |
| Phase 3Authorised | not given | Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform) | |
| Phase 2Authorised | not given | A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial) | |
| Phase 2Authorised | not given | PEMBROCABOSARC : COMBINATION OF PEMBROLIZUMAB AND CABOZANTINIB IN PATIENTS WITH ADVANCED SARCOMAS | |
| Phase 2Authorised | not given | Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial: ARCADIA study | |
| Phase 2Authorised | not given | MegaMOST - A multicenter, open-label, biology driven, Phase II study evaluating the activity of anti-cancer treatments targeting tumor molecular alterations/characteristics in advanced / metastatic tumors | |
| Phase 2Ended | not given | CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3 | |
| Phase 2Ended | not given | Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. | |
| Phase 2Ended | not given | A phase II, open-label, multicenter trial to investigate the clinical activity and safety of Cabozantinib in combination with avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3) | |
| Phase 2Authorised | not given | A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1). | |
| Phase 3Authorised | not given | Strategic treatment Pause of first-line Immune Check point inhibitor + Inhibitor in good or only one adverse prognostic factor in intermediate risk metastatic renal cell carcinoma (mRCC) with an objective response: a randomized, non-inferiority phase III study - SPICI | |
| Phase 2Authorised | not given | A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial | |
| Phase 4Authorised | not given | Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-reported-outcome evaluation (CABOLD) | |
| Phase 2Ended | not given | Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A phase II study (Immunocabo) | |
| Phase 4Authorised | not given | CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZED STUDY | |
| Phase 2Authorised | not given | Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation | |
| Phase 4Authorised | not given | Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: The CANIQOL multicentre study | |
| Phase 2Ended | not given | A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma | |
| Phase 2Authorised | not given | SKIPP2: Cabozantinib Dose Skipping as an Alternative to Dose Reductions | |
| Phase 4Authorised | not given | Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG | |
| Phase 3Authorised | not given | Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial. | |
| Phase 4Authorised | not given | Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma | |
| Phase 2Not authorised | not given | The role of serum KIM-1 and MAdCAM-1 dynamics in early prediction of the efficacy of de-escalated systemic treatment in advanced renal cell carcinoma (STELA study). | |
| Phase 2/3Authorised | not given | The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026